Phaseline

Companies › Engeneic

Engeneic: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Sep 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
E-EDV-D682
Bacterially derived nanocell (EDV) packaged with chemotherapeutic drug, targeted to cancer
–Phase 1Pancreatic Cancer, MetastaticSep 2028
EDV-GC
Bacterially derived nanocell (EDV) packaging alpha-galactosyl ceramide (GC) immunomodulato
–Phase 1Pancreatic Cancer, MetastaticSep 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07049055E-EDV-D682Phase 1Pancreatic Cancer, MetastaticOncologySep 2028
NCT07049055EDV-GCPhase 1Pancreatic Cancer, MetastaticOncologySep 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.